Cargando…

Meningioma animal models: a systematic review and meta-analysis

BACKGROUND: Animal models are widely used to study pathological processes and drug (side) effects in a controlled environment. There is a wide variety of methods available for establishing animal models depending on the research question. Commonly used methods in tumor research include xenografting...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersen, Mikkel Schou, Kofoed, Mikkel Seremet, Paludan-Müller, Asger Sand, Pedersen, Christian Bonde, Mathiesen, Tiit, Mawrin, Christian, Wirenfeldt, Martin, Kristensen, Bjarne Winther, Olsen, Birgitte Brinkmann, Halle, Bo, Poulsen, Frantz Rom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612271/
https://www.ncbi.nlm.nih.gov/pubmed/37898750
http://dx.doi.org/10.1186/s12967-023-04620-7
_version_ 1785128666298056704
author Andersen, Mikkel Schou
Kofoed, Mikkel Seremet
Paludan-Müller, Asger Sand
Pedersen, Christian Bonde
Mathiesen, Tiit
Mawrin, Christian
Wirenfeldt, Martin
Kristensen, Bjarne Winther
Olsen, Birgitte Brinkmann
Halle, Bo
Poulsen, Frantz Rom
author_facet Andersen, Mikkel Schou
Kofoed, Mikkel Seremet
Paludan-Müller, Asger Sand
Pedersen, Christian Bonde
Mathiesen, Tiit
Mawrin, Christian
Wirenfeldt, Martin
Kristensen, Bjarne Winther
Olsen, Birgitte Brinkmann
Halle, Bo
Poulsen, Frantz Rom
author_sort Andersen, Mikkel Schou
collection PubMed
description BACKGROUND: Animal models are widely used to study pathological processes and drug (side) effects in a controlled environment. There is a wide variety of methods available for establishing animal models depending on the research question. Commonly used methods in tumor research include xenografting cells (established/commercially available or primary patient-derived) or whole tumor pieces either orthotopically or heterotopically and the more recent genetically engineered models—each type with their own advantages and disadvantages. The current systematic review aimed to investigate the meningioma model types used, perform a meta-analysis on tumor take rate (TTR), and perform critical appraisal of the included studies. The study also aimed to assess reproducibility, reliability, means of validation and verification of models, alongside pros and cons and uses of the model types. METHODS: We searched Medline, Embase, and Web of Science for all in vivo meningioma models. The primary outcome was tumor take rate. Meta-analysis was performed on tumor take rate followed by subgroup analyses on the number of cells and duration of incubation. The validity of the tumor models was assessed qualitatively. We performed critical appraisal of the methodological quality and quality of reporting for all included studies. RESULTS: We included 114 unique records (78 using established cell line models (ECLM), 21 using primary patient-derived tumor models (PTM), 10 using genetically engineered models (GEM), and 11 using uncategorized models). TTRs for ECLM were 94% (95% CI 92–96) for orthotopic and 95% (93–96) for heterotopic. PTM showed lower TTRs [orthotopic 53% (33–72) and heterotopic 82% (73–89)] and finally GEM revealed a TTR of 34% (26–43). CONCLUSION: This systematic review shows high consistent TTRs in established cell line models and varying TTRs in primary patient-derived models and genetically engineered models. However, we identified several issues regarding the quality of reporting and the methodological approach that reduce the validity, transparency, and reproducibility of studies and suggest a high risk of publication bias. Finally, each tumor model type has specific roles in research based on their advantages (and disadvantages). Systematic review registration: PROSPERO-ID CRD42022308833. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04620-7.
format Online
Article
Text
id pubmed-10612271
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106122712023-10-29 Meningioma animal models: a systematic review and meta-analysis Andersen, Mikkel Schou Kofoed, Mikkel Seremet Paludan-Müller, Asger Sand Pedersen, Christian Bonde Mathiesen, Tiit Mawrin, Christian Wirenfeldt, Martin Kristensen, Bjarne Winther Olsen, Birgitte Brinkmann Halle, Bo Poulsen, Frantz Rom J Transl Med Review BACKGROUND: Animal models are widely used to study pathological processes and drug (side) effects in a controlled environment. There is a wide variety of methods available for establishing animal models depending on the research question. Commonly used methods in tumor research include xenografting cells (established/commercially available or primary patient-derived) or whole tumor pieces either orthotopically or heterotopically and the more recent genetically engineered models—each type with their own advantages and disadvantages. The current systematic review aimed to investigate the meningioma model types used, perform a meta-analysis on tumor take rate (TTR), and perform critical appraisal of the included studies. The study also aimed to assess reproducibility, reliability, means of validation and verification of models, alongside pros and cons and uses of the model types. METHODS: We searched Medline, Embase, and Web of Science for all in vivo meningioma models. The primary outcome was tumor take rate. Meta-analysis was performed on tumor take rate followed by subgroup analyses on the number of cells and duration of incubation. The validity of the tumor models was assessed qualitatively. We performed critical appraisal of the methodological quality and quality of reporting for all included studies. RESULTS: We included 114 unique records (78 using established cell line models (ECLM), 21 using primary patient-derived tumor models (PTM), 10 using genetically engineered models (GEM), and 11 using uncategorized models). TTRs for ECLM were 94% (95% CI 92–96) for orthotopic and 95% (93–96) for heterotopic. PTM showed lower TTRs [orthotopic 53% (33–72) and heterotopic 82% (73–89)] and finally GEM revealed a TTR of 34% (26–43). CONCLUSION: This systematic review shows high consistent TTRs in established cell line models and varying TTRs in primary patient-derived models and genetically engineered models. However, we identified several issues regarding the quality of reporting and the methodological approach that reduce the validity, transparency, and reproducibility of studies and suggest a high risk of publication bias. Finally, each tumor model type has specific roles in research based on their advantages (and disadvantages). Systematic review registration: PROSPERO-ID CRD42022308833. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04620-7. BioMed Central 2023-10-28 /pmc/articles/PMC10612271/ /pubmed/37898750 http://dx.doi.org/10.1186/s12967-023-04620-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Andersen, Mikkel Schou
Kofoed, Mikkel Seremet
Paludan-Müller, Asger Sand
Pedersen, Christian Bonde
Mathiesen, Tiit
Mawrin, Christian
Wirenfeldt, Martin
Kristensen, Bjarne Winther
Olsen, Birgitte Brinkmann
Halle, Bo
Poulsen, Frantz Rom
Meningioma animal models: a systematic review and meta-analysis
title Meningioma animal models: a systematic review and meta-analysis
title_full Meningioma animal models: a systematic review and meta-analysis
title_fullStr Meningioma animal models: a systematic review and meta-analysis
title_full_unstemmed Meningioma animal models: a systematic review and meta-analysis
title_short Meningioma animal models: a systematic review and meta-analysis
title_sort meningioma animal models: a systematic review and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612271/
https://www.ncbi.nlm.nih.gov/pubmed/37898750
http://dx.doi.org/10.1186/s12967-023-04620-7
work_keys_str_mv AT andersenmikkelschou meningiomaanimalmodelsasystematicreviewandmetaanalysis
AT kofoedmikkelseremet meningiomaanimalmodelsasystematicreviewandmetaanalysis
AT paludanmullerasgersand meningiomaanimalmodelsasystematicreviewandmetaanalysis
AT pedersenchristianbonde meningiomaanimalmodelsasystematicreviewandmetaanalysis
AT mathiesentiit meningiomaanimalmodelsasystematicreviewandmetaanalysis
AT mawrinchristian meningiomaanimalmodelsasystematicreviewandmetaanalysis
AT wirenfeldtmartin meningiomaanimalmodelsasystematicreviewandmetaanalysis
AT kristensenbjarnewinther meningiomaanimalmodelsasystematicreviewandmetaanalysis
AT olsenbirgittebrinkmann meningiomaanimalmodelsasystematicreviewandmetaanalysis
AT hallebo meningiomaanimalmodelsasystematicreviewandmetaanalysis
AT poulsenfrantzrom meningiomaanimalmodelsasystematicreviewandmetaanalysis